216 related articles for article (PubMed ID: 21059223)
1. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Thollet A; Vendrell JA; Payen L; Ghayad SE; Ben Larbi S; Grisard E; Collins C; Villedieu M; Cohen PA
Mol Cancer; 2010 Nov; 9():291. PubMed ID: 21059223
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.
Long M; Yin G; Liu L; Lin F; Wang X; Ren J; Wei J; Dong K; Zhang H
Cancer Gene Ther; 2012 Apr; 19(4):271-81. PubMed ID: 22281755
[TBL] [Abstract][Full Text] [Related]
3. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
Littlepage LE; Adler AS; Kouros-Mehr H; Huang G; Chou J; Krig SR; Griffith OL; Korkola JE; Qu K; Lawson DA; Xue Q; Sternlicht MD; Dijkgraaf GJ; Yaswen P; Rugo HS; Sweeney CA; Collins CC; Gray JW; Chang HY; Werb Z
Cancer Discov; 2012 Jul; 2(7):638-51. PubMed ID: 22728437
[TBL] [Abstract][Full Text] [Related]
4. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.
Krig SR; Miller JK; Frietze S; Beckett LA; Neve RM; Farnham PJ; Yaswen PI; Sweeney CA
Oncogene; 2010 Oct; 29(40):5500-10. PubMed ID: 20661224
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.
Mazumdar A; Henderson YC; El-Naggar AK; Sen S; Clayman GL
Head Neck; 2009 May; 31(5):625-34. PubMed ID: 19107951
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Zhao W; Song Y; Xu B; Zhan Q
Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
[TBL] [Abstract][Full Text] [Related]
7. Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp.
Li Y; Tang K; Zhang H; Zhang Y; Zhou W; Chen X
Mol Med Rep; 2011; 4(4):739-46. PubMed ID: 21584498
[TBL] [Abstract][Full Text] [Related]
8. Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.
Li Y; Zhou W; Tang K; Chen X; Feng Z; Chen J
Oncol Rep; 2017 Oct; 38(4):2011-2022. PubMed ID: 28849180
[TBL] [Abstract][Full Text] [Related]
9. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
12. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.
Sunters A; Fernández de Mattos S; Stahl M; Brosens JJ; Zoumpoulidou G; Saunders CA; Coffer PJ; Medema RH; Coombes RC; Lam EW
J Biol Chem; 2003 Dec; 278(50):49795-805. PubMed ID: 14527951
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells.
Lee HH; Zhu Y; Govindasamy KM; Gopalan G
Endocr Relat Cancer; 2008 Sep; 15(3):765-75. PubMed ID: 18469155
[TBL] [Abstract][Full Text] [Related]
14. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
16. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells.
Tanaka H; Nakamura M; Kameda C; Kubo M; Sato N; Kuroki S; Tanaka M; Katano M
Anticancer Res; 2009 Jun; 29(6):2147-57. PubMed ID: 19528475
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.
Scharer CD; Laycock N; Osunkoya AO; Logani S; McDonald JF; Benigno BB; Moreno CS
J Transl Med; 2008 Dec; 6():79. PubMed ID: 19077237
[TBL] [Abstract][Full Text] [Related]
18. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.
Lv K; Liu L; Wang L; Yu J; Liu X; Cheng Y; Dong M; Teng R; Wu L; Fu P; Deng W; Hu W; Teng L
PLoS One; 2012; 7(7):e40008. PubMed ID: 22808086
[TBL] [Abstract][Full Text] [Related]
19. The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.
Bellanger A; Donini CF; Vendrell JA; Lavaud J; Machuca-Gayet I; Ruel M; Vollaire J; Grisard E; Győrffy B; Bièche I; Peyruchaud O; Coll JL; Treilleux I; Maguer-Satta V; Josserand V; Cohen PA
J Pathol; 2017 May; 242(1):73-89. PubMed ID: 28207159
[TBL] [Abstract][Full Text] [Related]
20. [Effect of down-regulation of Oct4 gene on biological characteristics of MDA-MB-231 breast cancer stem cells].
Zhonghua Zhong Liu Za Zhi; 2015 Apr; 37(4):251-7. PubMed ID: 26462888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
